GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by respiratory syncytial virus due to certain ...

Graham Parry has given his Sell rating due to a combination of factors affecting GlaxoSmithKline’s Arexvy vaccine. The challenges highlighted include the limited effectiveness of a single shot ...

For the company’s closely watched respiratory syncytial virus (RSV) vaccine Arexvy, those challenges led to drastically reduced sales. After a stunning ascension to blockbuster status in its RSV ...

Preliminary data were announced from 2 clinical trials evaluating Arexvy (respiratory syncytial virus [RSV] vaccine, adjuvanted) in a broader population of adults at increased for RSV disease.

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial ... There are currently no RSV vaccines recommended for adults younger ...

Preliminary results from two trials showed that GSK’s respiratory syncytial virus (RSV) vaccine Arexvy has potential in younger adults with certain risk factors, potentially positioning the shot ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress ... Yet, those settlements carry no admission of liability. GSK also has agreed to a qui tam Valisure’s complaint.

in RSV-A and RSV-B nAbs that were comparable to AS01 E-adjuvanted AREXVY at Day 28, with no statistically significant differences observed. RSV-A nAbs: SCB-1019 induced GMTs in RSV-A nAbs of ...

Arexvy shows 62.9% efficacy against RSV-LRTD over three seasons in adults aged 60 and older. The vaccine demonstrates 67.4% efficacy against severe RSV-LRTD, with consistent safety data. Arexvy is ...

The news: Audi has just launched a new EV brand in China, and the company is making a bold branding move to set the vehicles ...